- Home
- RMTI vs BOLD Comparison
RMTI vs BOLD Comparison
Compare RMTI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMTI | BOLD |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 26.2M |
| IPO Year | 1998 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RMTI | BOLD |
|---|---|---|
| Price | $0.82 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 225.3K | 144.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.00 |
| 52 Week High | $2.41 | $3.12 |
Technical Indicators
Market Signals| Indicator | RMTI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 49.69 |
| Support Level | $0.78 | $1.17 |
| Resistance Level | $0.88 | $1.37 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 20.61 | 28.00 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.